| Symbol | KPRX |
|---|---|
| Name | KIORA PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 169 SAXONY RD., ENCINITAS, CA 92024 |
| Telephone | 858-224-9600 |
| Fax | — |
| — | |
| Website | https://www.kiorapharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001372514 |
| Description | Kiora Pharmaceuticals Inc is a clinical-stage specialty pharmaceutical company. It focuses on developing and commercializing products for treating diseases and disorders of the eye. It operates in one reportable segment operations and manages. Additional info from NASDAQ: |
(70% Positive) KIORA PHARMACEUTICALS INC (KPRX) Announces Clinical Development Update
Read moreKiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
Read moreDirector Stengone Carmine N. 🟢 acquired 25.0K shares (1 derivative) of KIORA PHARMACEUTICALS INC (KPRX) at $2.63 Transaction Date: Jun 10, 2026 | Filing ID: 000002
Read moreDirector Shapiro Aron 🟢 acquired 25.0K shares (1 derivative) of KIORA PHARMACEUTICALS INC (KPRX) at $2.63 Transaction Date: Jun 10, 2026 | Filing ID: 000002
Read moreDirector Parsons Erin 🟢 acquired 25.0K shares (1 derivative) of KIORA PHARMACEUTICALS INC (KPRX) at $2.63 Transaction Date: Jun 10, 2026 | Filing ID: 000001
Read moreDirector Hollander David 🟢 acquired 25.0K shares (1 derivative) of KIORA PHARMACEUTICALS INC (KPRX) at $2.63 Transaction Date: Jun 10, 2026 | Filing ID: 000002
Read moreDirector Walters-Hoffert Lisa 🟢 acquired 25.0K shares (1 derivative) of KIORA PHARMACEUTICALS INC (KPRX) at $2.63 Transaction Date: Jun 10, 2026 | Filing ID: 000002
Read moreDirector TYLE PRAVEEN 🟢 acquired 40.0K shares (1 derivative) of KIORA PHARMACEUTICALS INC (KPRX) at $2.63 Transaction Date: Jun 10, 2026 | Filing ID: 000061
Read moreNew Form 424B3 - KIORA PHARMACEUTICALS INC <b>Filed:</b> 2026-05-28 <b>AccNo:</b> 0001372514-26-000057 <b>Size:</b> 631 KB
Read moreNew Form EFFECT - KIORA PHARMACEUTICALS INC <b>Filed:</b> 2026-05-22 <b>AccNo:</b> 9999999995-26-001753 <b>Size:</b> 1 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06628947 | A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis … | Phase2 | Retinitis Pigmentosa | Recruiting | 2025-08-29 | 2027-08-01 | ClinicalTrials.gov |
| NCT06825702 | Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macu… | Phase2 | Macular Edema | Recruiting | 2025-05-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT05629364 | A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and … | Phase2 | Dry Eye Disease | Terminated | 2023-03-15 | 2024-01-09 | ClinicalTrials.gov |
| NCT05282953 | A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of … | Phase1 | Retinitis Pigmentosa | Completed | 2022-11-10 | 2026-03-24 | ClinicalTrials.gov |
| NCT05436288 | A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Ep… | Phase2 | Persistent Corneal Epithelial Defect | Completed | 2022-07-01 | 2023-01-22 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| 50 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| 100 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| Placebo (Sterile Saline or Balanced Salt Solution) | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| KIO-104 | Other | Phase PHASE2 | Macular Edema | RECRUITING | NCT06825702 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | COMPLETED | NCT05282953 |
| KIO-101 | Other | Phase PHASE2 | Dry Eye Disease | TERMINATED | NCT05629364 |
| KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) | Other | Phase PHASE2 | Persistent Corneal Epithelial Defect | COMPLETED | NCT05436288 |
| KIO-301 | Other | Phase PHASE1 | Retinitis Pigmentosa | RECRUITING | NCT05282953 |
| KIO-104 | Other | Phase PHASE2 | Macular Edema | RECRUITING | NCT06825702 |
| 50 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| 100 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| Placebo (Sterile Saline or Balanced Salt Solution) | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| KIO-104 | Other | Phase PHASE2 | Macular Edema | RECRUITING | NCT06825702 |
| 50 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| 100 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| Placebo (Sterile Saline or Balanced Salt Solution) | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| KIO-104 | Other | Phase PHASE2 | Macular Edema | RECRUITING | NCT06825702 |
| 50 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| 100 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| Placebo (Sterile Saline or Balanced Salt Solution) | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| KIO-104 | Other | Phase PHASE2 | Macular Edema | RECRUITING | NCT06825702 |
| 50 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| 100 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| Placebo (Sterile Saline or Balanced Salt Solution) | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| KIO-104 | Other | Phase PHASE2 | Macular Edema | RECRUITING | NCT06825702 |
| 50 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| 100 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| Placebo (Sterile Saline or Balanced Salt Solution) | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| KIO-104 | Other | Phase PHASE2 | Macular Edema | RECRUITING | NCT06825702 |
| 50 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| 100 μg KIO-301 | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| Placebo (Sterile Saline or Balanced Salt Solution) | Other | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| HC1119 | DRUG | Phase PHASE1 | Metastatic Castration Resistant Prostate Cancer | COMPLETED | NCT03778047 |
| Enzalutamide | DRUG | Phase PHASE1 | Metastatic Castration Resistant Prostate Cancer | COMPLETED | NCT03778047 |
| HP568 in combination with palbociclib | DRUG | Phase PHASE1 | Breast Cancer | NOT_YET_RECRUITING | NCT06757335 |
| HP568 | DRUG | Phase PHASE1 | Breast Cancer | NOT_YET_RECRUITING | NCT06757335 |
| placebo | DRUG | Phase PHASE3 | MCRPC | RECRUITING | NCT03851640 |
| HC-1119 | DRUG | Phase PHASE1 | Metastatic Castration Resistant Prostate Cancer | COMPLETED | NCT03774056 |
| HP518 -Dose Expansion | DRUG | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06155084 |
| HP518 - Dose Escalation | DRUG | Phase PHASE1 | Metastatic Castration-resistant Prostate Cancer | RECRUITING | NCT06155084 |
| KIO-104 | DRUG | Phase PHASE2 | Macular Edema | RECRUITING | NCT06825702 |
| 50 μg KIO-301 | DRUG | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| 100 μg KIO-301 | DRUG | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| Placebo (Sterile Saline or Balanced Salt Solution) | OTHER | Phase PHASE2 | Retinitis Pigmentosa | RECRUITING | NCT06628947 |
| KIO-101 | DRUG | Phase PHASE2 | Dry Eye Disease | TERMINATED | NCT05629364 |
| KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) | DRUG | Phase PHASE2 | Persistent Corneal Epithelial Defect | COMPLETED | NCT05436288 |
| KIO-301 | DRUG | Phase PHASE1 | Retinitis Pigmentosa | RECRUITING | NCT05282953 |